MHRA approves Rinvoq for ulcerative colitis

Hot on the heels of European Union authorization for the same indication, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Rinvoq (upadacitinib), from US drugmaker AbbVie (NYSE: ABBV), for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Upadacitinib has demonstrated efficacy in induction studies U-ACHIEVE and U-ACCOMPLISH as well as achieving the primary endpoint of clinical remission in the Phase III U-ACHIEVE maintenance study.5